Viewing Study NCT01588951



Ignite Creation Date: 2024-05-06 @ 12:28 AM
Last Modification Date: 2024-10-26 @ 10:50 AM
Study NCT ID: NCT01588951
Status: TERMINATED
Last Update Posted: 2018-08-14
First Post: 2012-04-27

Brief Title: Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Overview

Official Title: Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Status: TERMINATED
Status Verified Date: 2018-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Low accrual
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary objective of the trial is to compare the two-year relapse-free survival RFS of patients with acute myeloid leukemia AML presumed to be at high risk for relapse due to the presence of leukemia stem cells LSCs in their bone marrow at first complete remission CR1 who receive either standard cytarabine-based chemotherapy or allogeneic stem cell transplantation SCT
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NA_00071844 OTHER JHMIRB None